Drug Development Executive

Drug Development Executive

Share this post

Drug Development Executive
Drug Development Executive
Serum APRIL Levels Predictor of Lymphoma Risk in Sjogren's Disease
Basic/Translational Sciences

Serum APRIL Levels Predictor of Lymphoma Risk in Sjogren's Disease

Eswar Krishnan, MD's avatar
Eswar Krishnan, MD
Jun 12, 2025
∙ Paid

Share this post

Drug Development Executive
Drug Development Executive
Serum APRIL Levels Predictor of Lymphoma Risk in Sjogren's Disease
Share

Sjögren's Disease (SjD) is a chronic autoimmune disorder primarily causing dry eyes and mouth. Beyond these common symptoms, SjD carries a significant risk of B-cell non-Hodgkin lymphoma. This increased lymphoma risk is a primary concern, highlighting the urgent need for reliable biomarkers to identify at-risk individuals and guide treatment.

A recent pr…

Keep reading with a 7-day free trial

Subscribe to Drug Development Executive to keep reading this post and get 7 days of free access to the full post archives.

Already a paid subscriber? Sign in
© 2025 Eswar Krishnan
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share